[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-33114":3,"doc-seo-33114":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},33114,3848291630094,"Emma Wilson","https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45",7,"Healthcare","Reversal of Cognitive Decline: A Novel Therapeutic Program","The article presents a comprehensive, personalized therapeutic program grounded in Alzheimer’s disease pathogenesis, aiming to enhance metabolism in support of neurodegeneration reversal through a systems-oriented multi-modality approach termed MEND. The first 10 treated patients with Alzheimer’s disease–related memory loss, amnestic MCI, or subjective cognitive impairment showed subjective or objective cognitive improvement in 9 cases within 3–6 months; the exception was very late-stage Alzheimer’s. Functional work disruption improved, effects persisted up to 2.5 years, and findings support larger trials and a metabolic driver of early cognitive decline.","cbCaidRfB6KVJSn3","https://ap.wps.com/l/cbCaidRfB6KVJSn3","pdf",813391,1,11,"English","en","# Introduction\n## Magnitude of the problem\n## Failure of monotherapeutics\n## Preclinical studies","[{\"question\":\"What therapeutic approach does the article propose for reversing cognitive decline?\",\"answer\":\"It proposes a novel, comprehensive, personalized multi-modality program based on Alzheimer’s disease pathogenesis, designed to enhance metabolism for neurodegeneration reversal (MEND).\"},{\"question\":\"How did the first 10 patients respond to the program?\",\"answer\":\"Nine of 10 patients with Alzheimer’s-related memory loss, amnestic MCI, or subjective cognitive impairment reported subjective or objective cognitive improvement within 3–6 months; the single failure involved a patient with very late-stage Alzheimer’s.\"},{\"question\":\"Why does the author argue that combination/system-based therapy may work better than monotherapy for Alzheimer’s?\",\"answer\":\"The article notes repeated failures of monotherapeutics and suggests that Alzheimer’s involves an extensive network of interacting molecular processes, making a network-based combination therapeutics strategy potentially more effective.\"}]",1782202950,28,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"reversal-of-cognitive-decline-a-novel-therapeutic-program","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/healthcare/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/reversal-of-cognitive-decline-a-novel-therapeutic-program/33114/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-06-23",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What therapeutic approach does the article propose for reversing cognitive decline?","Question",{"text":73,"@type":74},"It proposes a novel, comprehensive, personalized multi-modality program based on Alzheimer’s disease pathogenesis, designed to enhance metabolism for neurodegeneration reversal (MEND).","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How did the first 10 patients respond to the program?",{"text":78,"@type":74},"Nine of 10 patients with Alzheimer’s-related memory loss, amnestic MCI, or subjective cognitive impairment reported subjective or objective cognitive improvement within 3–6 months; the single failure involved a patient with very late-stage Alzheimer’s.",{"name":80,"@type":71,"acceptedAnswer":81},"Why does the author argue that combination/system-based therapy may work better than monotherapy for Alzheimer’s?",{"text":82,"@type":74},"The article notes repeated failures of monotherapeutics and suggests that Alzheimer’s involves an extensive network of interacting molecular processes, making a network-based combination therapeutics strategy potentially more effective.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]